Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2 infection

Objectives Antigen rapid diagnostic tests (Ag-RDT) have been developed as reliable tools to control the SARS-CoV-2 pandemic. The objective of our study was to evaluate the diagnostic performance of two Ag-RDTs. Methods We evaluated CerTest SARS-CoV-2 Ag One Step Card Test and Panbio COVID-19 Ag Rapid Test Device Ag-RDTs. We included 320 nasopharyngeal samples: 150 PCR negative samples to assess the specificity and 170 PCR positive samples to evaluate the sensitivity. We also evaluated their sensitivity according to cycle threshold (Ct) values and the time from the onset of symptoms. Tests were compared using the McNemar?s test and agreement was evaluated using the kappa score (k). Results Both Ag-RDTs showed a specificity of 100 %. Overall sensitivity was 53.5 % for CerTest and 60.0 % for Panbio. For samples with 25, sensitivity was 94.0 % for CerTest and 96.4 % for Panbio (p = 0.500). Regarding samples with Ct>25, sensitivity was 14.0 % for CerTest and 24.4 % for Panbio (p = 0.004). Sensitivity for samples within the first 5 days after the onset of symptoms were 84.8 % for CerTest and 91.3 % for Panbio (p = 0.250) and notably decreased for samples taken after the fifth day. Both Ag-RDTs showed an excellent agreement between them (agreement = 96.7 %, k = 0.920). Agreement with PCR was also excellent for high viral load samples (Ct<25) for CerTest (98.0 %, k = 0.954) and Panbio (98.8 %, k = 0.973). Conclusions CerTest SARS-CoV-2 and Panbio COVID-19 Ag showed excellent performance and agreement results for samples with high viral loads (Ct 25) or samples taken within the first 5 days after the onset of symptoms

La reparación económica a la víctima en el sistema de justicia

En este libro se recogen las investigaciones llevadas a cabo en el marco de los Trabajos Fin de Grado de la Universidad Carlos III de Madrid en los dobles grados de Derecho y Administración de Empresas, Derecho y Economía durante los cursos 2015/16 y 2016/17. El objetivo principal es evaluar la eficacia de la reparación económica a la víctima. Para ello, se realizó un estudio de campo de las ejecutorias en los Juzgados de lo Penal y la Audiencia Provincial de Madrid en dos etapas, octubre de 2015 y octubre de 2016, , excluyendo delitos menores y delitos relacionados con delitos de tránsito y violencia de género, así como aquellos donde no hubiera víctima.Este trabajo ha sido subvencionado en parte por los proyectos DER2015-66435-P y MTM2014-56535-R, Ministerio de Economía y Competitividad, y se enmarca en el Proyecto innovación docente de la Universidad Carlos III de Madrid titulado Eficacia y Eficiencia de la Justicia, curso 2016/2017.Prólogo / Daniel Peña (pp. 19-20). -- La ineficacia del sistema español en la compensación a través del proceso / Helena Soleto y Aurea Grané (pp. 23-97). -- Asistencia jurídica y turno de oficio para la víctima / Alicia Calvo Barceló (pp. 101-138). -- Competencia judicial en ejecución penal / Alberto Rodríguez Abad (pp. 141-175). -- El fiscal en la ejecución / María García Navarro (pp. 177-214). -- La participación de la víctima en la ejecución / Sara González Pérez (pp. 215-247). -- Investigación patrimonial del condenado / Radad Sennouni El Harti (pp. 249-277). -- La suspensión de la pena privativa y libertad condicional / Sara Jiménez Olbea (pp. 281-306). -- La insolvencia del condenado / Catalina Guzmán Guzmán (pp. 307-324). -- Eficacia del pago y percepción de impunidad: consecuencias de la reparación en el condenado / Rosa González Espejo (pp. 325-342). -- Delitos contra la libertad sexual / María Belén Combarros Gómez (pp. 345-386). -- La víctima del delito de trata de seres humanos e inmigración ilegal / Eduardo Sagra González (pp. 387-407). -- La reparación en violencia de género / Marina García-Navas Gómez (pp. 409-439). -- Reparación en delitos contra la Administración Pública / Irea Riobó Mayo (pp. 441-459). -- La reparación económica en el caso Madrid Arena / Lucía Gimeno Malumbres (pp. 461-487). -- La reparación en el proceso de menores / Miriam López-Terradas Paniagua (pp. 489-513). -- La atenuante por reparación del daño / Adriana Noel Afonso Carracedo (pp. 517-540). -- Reparación y modelos de justicia reparativa / Victoria Martínez Martínez (pp. 541-567). -- Elementos básicos de justicia restaurativa / Mireia Galindo Perpiñán (pp. 569-614). -- El acuerdo de reparación en la justicia reparativa / Ainhoa Berrocal Cañadas (pp. 615-634). -- La indemnización a las víctimas en el Derecho comparado / Alba Peña Díaz (pp. 637-650). -- Las indemnizaciones de la Ley 35/1995 / Inmaculada Ramírez Rodríguez (pp. 651-702). -- El pago de indemnizaciones por el Estado en terrorismo / Ana Pérez Campón (pp. 703-734)

Famílies botàniques de plantes medicinals

Facultat de Farmàcia, Universitat de Barcelona. Ensenyament: Grau de Farmàcia, Assignatura: Botànica Farmacèutica, Curs: 2013-2014, Coordinadors: Joan Simon, Cèsar Blanché i Maria Bosch.Els materials que aquí es presenten són els recull de 175 treballs d’una família botànica d’interès medicinal realitzats de manera individual. Els treballs han estat realitzat per la totalitat dels estudiants dels grups M-2 i M-3 de l’assignatura Botànica Farmacèutica durant els mesos d’abril i maig del curs 2013-14. Tots els treballs s’han dut a terme a través de la plataforma de GoogleDocs i han estat tutoritzats pel professor de l’assignatura i revisats i finalment co-avaluats entre els propis estudiants. L’objectiu principal de l’activitat ha estat fomentar l’aprenentatge autònom i col·laboratiu en Botànica farmacèutica

Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours : results from the COPPADIS cohort

The study was aimed at analysing the frequency of impulse control disorders (ICDs) and compulsive behaviours (CBs) in patients with Parkinson's disease (PD) and in control subjects (CS) as well as the relationship between ICDs/CBs and motor, nonmotor features and dopaminergic treatment in PD patients. Data came from COPPADIS-2015, an observational, descriptive, nationwide (Spain) study. We used the validated Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) for ICD/CB screening. The association between demographic data and ICDs/CBs was analyzed in both groups. In PD, this relationship was evaluated using clinical features and treatment-related data. As result, 613 PD patients (mean age 62.47 ± 9.09 years, 59.87% men) and 179 CS (mean age 60.84 ± 8.33 years, 47.48% men) were included. ICDs and CBs were more frequent in PD (ICDs 12.7% vs. 1.6%, p < 0.001; CBs 7.18% vs. 1.67%, p = 0.01). PD patients had more frequent previous ICDs history, premorbid impulsive personality and antidepressant treatment (p < 0.05) compared with CS. In PD, patients with ICDs/CBs presented younger age at disease onset, more frequent history of previous ICDs and premorbid personality (p < 0.05), as well as higher comorbidity with nonmotor symptoms, including depression and poor quality of life. Treatment with dopamine agonists increased the risk of ICDs/CBs, being dose dependent (p < 0.05). As conclusions, ICDs and CBs were more frequent in patients with PD than in CS. More nonmotor symptoms were present in patients with PD who had ICDs/CBs compared with those without. Dopamine agonists have a prominent effect on ICDs/CBs, which could be influenced by dose

Fifth European Dirofilaria and Angiostrongylus Days (FiEDAD) 2016

Peer reviewe

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio